SEC Form 4 · accession 0001179110-16-025586
SUNESIS PHARMACEUTICALS INC · SNSS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geoffrey M. Parker
Director
Period of report
May 24, 2016
Accepted (ET)
May 26, 2016 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001061027
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 24, 2016 | P | 30,000 | $0.4627 | A | 30,000 | D | |
| Common StockF1 | May 25, 2016 | P | 22,505 | $0.4858 | A | 52,505 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.46 to $0.495, inclusive. The reporting person undertakes to provide Sunesis Pharmaceuticals, Inc., any security holder of Sunesis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote(1)to this Form 4.